NASDAQ:JNCE

Jounce Therapeutics News Headlines

$7.79
-0.06 (-0.76 %)
(As of 09/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.35
$7.91
50-Day Range
$5.04
$7.85
52-Week Range
$5.03
$14.84
Volume1.48 million shs
Average Volume508,040 shs
Market Capitalization$399.08 million
P/E RatioN/A
Dividend YieldN/A
Beta1.11

Media Mentions By Week

Jounce Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

JNCE
News Sentiment

0.82

0.31

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

JNCE Articles
This Week

3

1

JNCE Articles
Average Week

Get Jounce Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter.

Jounce Therapeutics (NASDAQ JNCE) News Headlines Today

SourceHeadline
Jounce Therapeutics Appoints Jigar Raythatha to its Board of DirectorsJounce Therapeutics Appoints Jigar Raythatha to its Board of Directors
finance.yahoo.com - September 15 at 8:16 AM
Jounce Therapeutics (NASDAQ:JNCE) Stock Rating Upgraded by Raymond JamesJounce Therapeutics (NASDAQ:JNCE) Stock Rating Upgraded by Raymond James
americanbankingnews.com - September 14 at 8:52 AM
 Analysts Expect Jounce Therapeutics, Inc. (NASDAQ:JNCE) Will Announce Quarterly Sales of $12.87 Million Analysts Expect Jounce Therapeutics, Inc. (NASDAQ:JNCE) Will Announce Quarterly Sales of $12.87 Million
americanbankingnews.com - September 4 at 2:12 AM
$12.87 Million in Sales Expected for Jounce Therapeutics, Inc. (NASDAQ:JNCE) This Quarter$12.87 Million in Sales Expected for Jounce Therapeutics, Inc. (NASDAQ:JNCE) This Quarter
americanbankingnews.com - September 4 at 2:12 AM
Jounce Therapeutics, Inc. (NASDAQ:JNCE) Expected to Announce Earnings of -$0.39 Per ShareJounce Therapeutics, Inc. (NASDAQ:JNCE) Expected to Announce Earnings of -$0.39 Per Share
americanbankingnews.com - September 2 at 7:20 PM
Jounce Therapeutics to Present at Upcoming Investor Conferences in SeptemberJounce Therapeutics to Present at Upcoming Investor Conferences in September
finance.yahoo.com - September 2 at 8:22 AM
Jounce Therapeutics, Inc. (NASDAQ:JNCE) Receives Average Rating of "Buy" from BrokeragesJounce Therapeutics, Inc. (NASDAQ:JNCE) Receives Average Rating of "Buy" from Brokerages
americanbankingnews.com - August 30 at 5:26 AM
Jounce Therapeutics, Inc.(JNCE)Jounce Therapeutics, Inc.(JNCE)
fool.com - August 20 at 5:34 PM
Rainbows and Unicorns: Jounce Therapeutics, Inc. (NASDAQ:JNCE) Analysts Just Became A Lot More OptimisticRainbows and Unicorns: Jounce Therapeutics, Inc. (NASDAQ:JNCE) Analysts Just Became A Lot More Optimistic
finance.yahoo.com - August 7 at 12:36 PM
Jounce Therapeutics, Inc. 2021 Q2 - Results - Earnings Call PresentationJounce Therapeutics, Inc. 2021 Q2 - Results - Earnings Call Presentation
seekingalpha.com - August 6 at 3:06 AM
Jounce Therapeutics, inc (JNCE) Q2 2021 Earnings Call TranscriptJounce Therapeutics, inc (JNCE) Q2 2021 Earnings Call Transcript
finance.yahoo.com - August 5 at 5:38 PM
Jounce Therapeutics, Inc. (JNCE) Reports Q2 Loss, Tops Revenue EstimatesJounce Therapeutics, Inc. (JNCE) Reports Q2 Loss, Tops Revenue Estimates
finance.yahoo.com - August 5 at 12:38 PM
Jounce Therapeutics Reports Second Quarter 2021 Financial ResultsJounce Therapeutics Reports Second Quarter 2021 Financial Results
finance.yahoo.com - August 5 at 7:37 AM
Were Hedge Funds Right About Jounce Therapeutics, Inc. (JNCE)?Were Hedge Funds Right About Jounce Therapeutics, Inc. (JNCE)?
finance.yahoo.com - July 30 at 2:00 PM
Jounce Therapeutics to Announce Second Quarter 2021 Financial Results and Host a Conference Call on Thursday, August 5, 2021Jounce Therapeutics to Announce Second Quarter 2021 Financial Results and Host a Conference Call on Thursday, August 5, 2021
finance.yahoo.com - July 29 at 9:10 AM
Jounce Therapeutics to Participate in William Blairs Biotech Focus ConferenceJounce Therapeutics to Participate in William Blair's Biotech Focus Conference
marketwatch.com - July 8 at 7:34 AM
Jounce Therapeutics to Participate in William Blair’s Biotech Focus ConferenceJounce Therapeutics to Participate in William Blair’s Biotech Focus Conference
finance.yahoo.com - July 7 at 10:14 AM
News Flash: Analysts Just Made A Meaningful Upgrade To Their Jounce Therapeutics, Inc. (NASDAQ:JNCE) ForecastsNews Flash: Analysts Just Made A Meaningful Upgrade To Their Jounce Therapeutics, Inc. (NASDAQ:JNCE) Forecasts
ca.finance.yahoo.com - June 27 at 5:55 PM
Industry Analysts Just Upgraded Their Jounce Therapeutics, Inc. (NASDAQ:JNCE) Revenue Forecasts By 16%Industry Analysts Just Upgraded Their Jounce Therapeutics, Inc. (NASDAQ:JNCE) Revenue Forecasts By 16%
nasdaq.com - June 16 at 10:01 AM
Jounce Therapeutics to Host Virtual R&D Day on June 23, 2021Jounce Therapeutics to Host Virtual R&D Day on June 23, 2021
feeds.benzinga.com - June 16 at 8:20 AM
Why Jounce Therapeutics Bounced Higher TodayWhy Jounce Therapeutics Bounced Higher Today
finance.yahoo.com - June 15 at 6:37 PM
Jounce Therapeutics Shares Rise 13% on IND Clearance for Cancer TreatmentJounce Therapeutics Shares Rise 13% on IND Clearance for Cancer Treatment
marketwatch.com - June 15 at 1:37 PM
Jounce Therapeutics to Participate in Fireside Chat at the Raymond James Human Health Innovation ConferenceJounce Therapeutics to Participate in Fireside Chat at the Raymond James Human Health Innovation Conference
finance.yahoo.com - June 14 at 9:19 AM
Shareholders Will Probably Hold Off On Increasing Jounce Therapeutics, Inc.s (NASDAQ:JNCE) CEO Compensation For The Time BeingShareholders Will Probably Hold Off On Increasing Jounce Therapeutics, Inc.'s (NASDAQ:JNCE) CEO Compensation For The Time Being
nasdaq.com - June 12 at 7:37 PM
Shareholders May Be A Bit More Conservative With Jounce Therapeutics, Inc.s (NASDAQ:JNCE) CEO Compensation For NowShareholders May Be A Bit More Conservative With Jounce Therapeutics, Inc.'s (NASDAQ:JNCE) CEO Compensation For Now
finance.yahoo.com - June 12 at 2:37 PM
Jounce Therapeutics Presents Trial in Progress Posters on the INNATE and SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual MeetingJounce Therapeutics Presents Trial in Progress Posters on the INNATE and SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
finance.yahoo.com - June 4 at 9:46 AM
Jounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q1 2021 Results - Earnings Call TranscriptJounce Therapeutics, Inc. (JNCE) CEO Rich Murray on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 6 at 7:06 AM
Jounce Therapeutics, Inc. (JNCE) Q1 2021 Earnings Call TranscriptJounce Therapeutics, Inc. (JNCE) Q1 2021 Earnings Call Transcript
finance.yahoo.com - May 4 at 5:21 PM
Jounce Therapeutics Reports First Quarter 2021 Financial ResultsJounce Therapeutics Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 4 at 7:19 AM
Companies Like Jounce Therapeutics (NASDAQ:JNCE) Are In A Position To Invest In GrowthCompanies Like Jounce Therapeutics (NASDAQ:JNCE) Are In A Position To Invest In Growth
finance.yahoo.com - May 2 at 1:09 PM
Jounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE and the Phase 2 SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual MeetingJounce Therapeutics to Present Trial in Progress Posters on the Phase 1 INNATE and the Phase 2 SELECT Clinical Trials at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting
finance.yahoo.com - April 28 at 8:53 AM
Jounce Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on Tuesday, May 4, 2021Jounce Therapeutics to Announce First Quarter 2021 Financial Results and Host Conference Call on Tuesday, May 4, 2021
finance.yahoo.com - April 27 at 12:19 PM
If You Had Bought Jounce Therapeutics (NASDAQ:JNCE) Stock A Year Ago, You Could Pocket A 85% Gain TodayIf You Had Bought Jounce Therapeutics (NASDAQ:JNCE) Stock A Year Ago, You Could Pocket A 85% Gain Today
nasdaq.com - April 22 at 6:40 PM
Jounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific OfficerJounce Therapeutics Appoints Dmitri Wiederschain, Ph.D., as Chief Scientific Officer
finance.yahoo.com - April 12 at 8:23 AM
Jounce Therapeutics Presents Preclinical Data...Jounce Therapeutics Presents Preclinical Data...
benzinga.com - April 11 at 9:03 AM
Jounce Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment OptionJounce Therapeutics Announces Closing of Public Offering and Full Exercise of Over-Allotment Option
finance.yahoo.com - March 12 at 12:04 PM
Jounce Therapeutics to Present Preclinical Data from JTX-8064 Program at the 2021 American Association for Cancer Research Virtual (AACR) Annual MeetingJounce Therapeutics to Present Preclinical Data from JTX-8064 Program at the 2021 American Association for Cancer Research Virtual (AACR) Annual Meeting
finance.yahoo.com - March 10 at 6:30 PM
Jounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common StockJounce Therapeutics Announces Pricing of $56.25 Million Public Offering of Common Stock
finance.yahoo.com - March 10 at 3:27 AM
Jounce Therapeutics Announces Proposed Offering of Common StockJounce Therapeutics Announces Proposed Offering of Common Stock
finance.yahoo.com - March 9 at 5:07 PM
Need To Know: Analysts Are Much More Bullish On Jounce Therapeutics, Inc. (NASDAQ:JNCE)Need To Know: Analysts Are Much More Bullish On Jounce Therapeutics, Inc. (NASDAQ:JNCE)
finance.yahoo.com - March 2 at 7:56 AM
Jounce Therapeutics, Inc. (JNCE) Q4 2020 Earnings Call TranscriptJounce Therapeutics, Inc. (JNCE) Q4 2020 Earnings Call Transcript
finance.yahoo.com - February 26 at 6:03 PM
Notable Thursday Option Activity: DG, JNCE, AMCNotable Thursday Option Activity: DG, JNCE, AMC
nasdaq.com - February 25 at 5:01 PM
Jounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial ResultsJounce Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - February 25 at 7:00 AM
Jounce Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021Jounce Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Thursday, February 25, 2021
finance.yahoo.com - February 18 at 9:21 AM
Jounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of DirectorsJounce Therapeutics Appoints Luisa Salter-Cid, Ph.D., to its Board of Directors
finance.yahoo.com - February 12 at 8:09 AM
JNCE Feb 2021 15.000 putJNCE Feb 2021 15.000 put
au.finance.yahoo.com - January 28 at 6:13 PM
JNCE Feb 2021 10.000 putJNCE Feb 2021 10.000 put
au.finance.yahoo.com - January 26 at 11:29 PM
JNCE Feb 2021 15.000 callJNCE Feb 2021 15.000 call
au.finance.yahoo.com - January 26 at 11:29 PM
JNCE Feb 2021 10.000 callJNCE Feb 2021 10.000 call
au.finance.yahoo.com - January 26 at 6:29 PM
Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and PD-1 Inhibitor Combination Therapy in Patients with Advanced Solid TumorsJounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and PD-1 Inhibitor Combination Therapy in Patients with Advanced Solid Tumors
finance.yahoo.com - January 13 at 8:15 AM
Get Jounce Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 9/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.